{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:17:11Z","timestamp":1777576631520,"version":"3.51.4"},"reference-count":8,"publisher":"National Center for Global Health and Medicine (JST)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.35772\/ghm.2024.01078","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T22:15:15Z","timestamp":1735251315000},"page":"64-66","source":"Crossref","is-referenced-by-count":3,"title":["Clinical potential of SAG-524: A novel HBV RNA destabilizer with a unique mechanism of action"],"prefix":"10.35772","volume":"7","author":[{"given":"Yasuhito","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chang ML, Liaw YF. Emerging therapies for chronic hepatitis B and the potential for a functional cure. Drugs. 2023; 83:367-388.","DOI":"10.1007\/s40265-023-01843-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: An overview and prospectus. Nat Rev Drug Discov. 2021; 20:427-453.","DOI":"10.1038\/s41573-021-00162-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020; 19:673-694.","DOI":"10.1038\/s41573-020-0075-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yuen MF, Heo J, Jang JW, <i>et al.<\/i> Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial. Nat Med. 2021; 27:1725-1734.","DOI":"10.1038\/s41591-021-01513-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yuen MF, Lim SG, Plesniak R, <i>et al. <\/i>Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022; 387:1957-1968.","DOI":"10.1056\/NEJMoa2210027"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mueller H, Wildum S, Luangsay S, <i>et al. <\/i>A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018; 68:412-420.","DOI":"10.1016\/j.jhep.2017.10.014"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Watanabe T, Hayashi S, Zhaoyu Y, Inada H, Nagaoka K, Tateyama M, Tanaka Y. A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA. J Gastroenterol. 2024; 59:315-328.","DOI":"10.1007\/s00535-023-02070-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ko C, Michler T, Protzer U. Novel viral and host targets to cure hepatitis B. Curr Opin Virol. 2017; 24:38-45.","DOI":"10.1016\/j.coviro.2017.03.019"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/1\/7_2024.01078\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T04:10:11Z","timestamp":1741407011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/7\/1\/7_2024.01078\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2024.01078","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"2024.01078"}}